BioSpace

RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish

Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.

By BioSpace

1 min read
RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights